CXCR4 antagonist: the publicly traded company X4 Pharmaceuticals (XFOR) makes an oral one. On the Pipeline part of their website, they seem to say they'll do an Oncology indication trial when they can find a partner.

Is the progress of their small molecule held back by management? Could happen, right?

I love our LL molecule, and like our new management so far. Fingers crossed for progress in '23.